| Date Filed | Type | Description |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/01/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 06/21/2019 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/20/2019 |
8-K
| Appointed a new director|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 18, 2019 ARCTURUS THERAPEUTICS HOLDINGS INC. Delaware 001-38942 32-0595345 10628 Science Center Drive, Suite 250 San Diego, California 92121 Registrant's telephone number, including area code: 900-2660 Arcturus Therapeutics Ltd. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d...",
"Registration Rights Agreement, between the Company and Ultragenyx Pharmaceutical Inc",
"Equity Purchase Agreement, between the Company and Ultragenyx Pharmaceutical Inc",
"Third Amendment, to Research Collaboration and License Agreement, as amended on October 17, 2017 and April 20, 2018, between the Company and Ultragenyx Pharmaceutical Inc",
"Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases" |
|
| 05/20/2019 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/13/2019 |
8-K
| Quarterly results |
| 05/10/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
| 04/15/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/12/2019 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/11/2019 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 04/10/2019 |
10-K/A
| Annual Report for the period ended December 31, 2018 [amend] |
| 03/15/2019 |
10-K
| Annual Report for the period ended December 31, 2018 |
| 02/27/2019 |
8-K
| Quarterly results |
| 02/20/2019 |
SC 13G/A
| Brosh Capital L.P. reports a 4.4% stake in Arcturus Therapeutics Ltd |
| 02/14/2019 |
SC 13G
| ARK Investment Management LLC reports a 7.6% stake in ARCTURUS THERAPEUTICS LTD. |
| 02/11/2019 |
4
| Payne Joseph E (President and CEO) has filed a Form 4 on Arcturus Therapeutics Ltd.|
Txns:
| Granted 60,000 options to buy
@ $4.99, valued at
$299.4k
|
|
| 02/11/2019 |
4
| Kummerfeld Keith C (Vice President of Finance) has filed a Form 4 on Arcturus Therapeutics Ltd.|
Txns:
| Granted 10,000 options to buy
@ $4.99, valued at
$49.9k
|
|
| 02/11/2019 |
4
| Chivukula Pad (Chief Scientific Officer & COO) has filed a Form 4 on Arcturus Therapeutics Ltd.|
Txns:
| Granted 1,667 options to buy
@ $4.99, valued at
$8.3k
Granted 38,333 options to buy
@ $4.99, valued at
$191.3k
|
|
| 02/11/2019 |
8-K
| Quarterly results |
| 01/25/2019 |
SC 13G/A
| FRANKLIN RESOURCES INC reports a 0% stake in ARCTURUS THERAPEUTICS LTD. |
| 01/02/2019 |
3
| Kummerfeld Keith C (Vice President of Finance) has filed a Form 3 on Arcturus Therapeutics Ltd. |
| 01/02/2019 |
3
| Chivukula Pad (Chief Scientific Officer & COO) has filed a Form 3 on Arcturus Therapeutics Ltd. |
| 01/02/2019 |
3
| Payne Joseph E (President and CEO) has filed a Form 3 on Arcturus Therapeutics Ltd. |
| 01/02/2019 |
3
| Marquet Magda (Director) has filed a Form 3 on Arcturus Therapeutics Ltd. |
| 01/02/2019 |
3
| SASSINE ANDY (CFO) has filed a Form 3 on Arcturus Therapeutics Ltd. |
| 01/02/2019 |
3
| BARLOW JAMES F (Director) has filed a Form 3 on Arcturus Therapeutics Ltd. |
| 01/02/2019 |
3
| FARRELL PETER C (Director) has filed a Form 3 on Arcturus Therapeutics Ltd. |
| 11/28/2018 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 11/20/2018 |
SC 13D/A
| Payne Joseph E reports a 13.7% stake in Arcturus Therapeutics Ltd. |
| 10/18/2018 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 10/15/2018 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 10/15/2018 |
6-K
| Quarterly results |
| 10/15/2018 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 10/01/2018 |
6-K
| Quarterly results |
|